Valuation dashboard for ADMA Biologics, Inc. (ADMA) with P/E 15.80, P/B 6.18, EV/EBITDA 10.9 and dividend yield 0.00%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
ADMA Biologics, Inc. functions as a biopharmaceutical company specializing in the development, manufacturing, and commercialization of advanced biologic therapies derived from blood plasma. These specialized products are engineered to address immune system disorders and infectious diseases, catering to markets across the United States and internationally.
Analysis Summary
ADMA Biologics, Inc. reported revenue of $510.2M in the most recent fiscal year, growing at a 5-year CAGR of 64.6%.
Trailing-twelve-month margins: gross margin 64.7%, operating margin 42.3%, net margin 33.0%.
At $11.06 (closing price, November 2, 2026), ADMA trades at a P/E of 15.80 and an ROE of 39.59%. Market capitalisation stands at $2.5B.
Balance sheet quality for ADMA: debt-to-equity ratio of 0.50, current ratio of 6.97 over the last 12 months. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| P/E Ratio | 15.80 |
| Price / Book | 6.18 |
| EV / EBITDA | 10.9 |
| Dividend Yield | 0.00% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| ADMA | ADMA Biologics, Inc. | $2.5B | 15.80 | 6.18 | 39.6% |
| GRFS | Grifols, S.A. | $7.2B | 16.42 | 1.35 | 8.4% |
| VRTX | Vertex Pharmaceuticals Incorporated | $140.2B | 35.60 | 4.28 | 17.5% |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $134.0B | 30.25 | 6.57 | 23.3% |
| REGN | Regeneron Pharmaceuticals, Inc. | $99.0B | 21.24 | 2.92 | 15.1% |
| MRNA | Moderna, Inc. | $88.2B | 12.93 | -39.2% | |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $86.5B | 19.22 | 2.62 | 13.8% |
| ARGX | argenx SE | $55.0B | 41.27 | 6.54 | 16.9% |
Price
| Price | $11.06 (closing price, November 2, 2026) |
| Market Cap | $2.5B |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | 39.59% |
| Return on Invested Capital | 27.55% |
| Return on Assets | 24.69% |
| Gross Margin | 64.71% |
| Operating Margin | 42.26% |
| Net Margin | 32.98% |
Related companies: GRFS · VRTX · 0QZU.L · REGN · MRNA · 0R2M.L · ARGX · 0QNO.L
Explore sector: Healthcare · Biotechnology
More sections of ADMA: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks